Kornimate/medical-research-clean huggingface dataset:
right ventricular and pulmonary artery evaluation by cmr

Conditions: Pulmonary Hypertension

Summary: pulmonary hypertension results in right ventricle dysfunction. cardiac magnetic resonance derived rv ejection fraction is a prognostic value in this condition. right ventricular geometry, function, morphology as well as pulmonary arterial stiffness and size may be evaluated by cardiac magnetic resonance imaging and could have great importance in evaluation of pulmonary hypertension prognosis and outcomes.

pulmonary hypertension is defined as an increase in mean pulmonary artery pressure \> 25 mmhg evaluated by right heart catheterisation. over time increased pulmonary artery pressure eventually causes vascular remodelling and right ventricular dysfunction. the right and left ventricles interact sharing a common pericardial sac and interventricular septum. frequently right ventricle dysfunction reflects clinical ph worsening. the aim of this study was to assess the geometry, function and morphology of right ventricle and also pulmonary artery diameter and stiffness in pulmonary hypertension patients by cardiovascular magnetic resonance. patients are recruited from the hospital of lithuanian university of health sciences kaunas clinics pulmonary hypertension center. study inclusion criteria: 1. patient with diagnosed pulmonary hypertension 2. rhc, 6mwt, echocardiography, nt-pro bnp, cmr performed in one month period. 3. patients who signed study informed consent form. study exclusion criteria: 1. coronary and valvular heart disease 2. atrial fibrillation 3. expressed shortness of breath 4. claustrophobia. suspected number of participants - 100. data analysis statistical analyses will be performed using spss 22.0 package (spss, chicago, il, usa). continuous variables will be expressed as mean +/- standard deviation, skewed variables as median (interquartile range). chi square test will be used for qualitative parameters. for continuous variables, differences between two groups will be compared using non-parametric mann-whitney u test. relation between variables will be assessed using spearman correlation coefficient. univariate analysis of predictors for survival will be used. in order to assess minimally false negative and minimally false positive results with greatest accuracy, the method of roc (receiver operating characteristics) curve will be used. the optimal values will be separated out the different groups (survival/non-survival) with the highest accuracy (minimal false negative and false positive). survival curves will be established by the kaplan-meier estimation method. cox regression analysis will be used to identify independent predictor of outcomes. two-tailed probability values at p\<0,05 will be considered statistically significant.

Eligibility criteria:
inclusion criteria: 1. patient with diagnosed pulmonary hypertension 2. rhc, 6mwt, echocardiography, nt-pro bnp, cmr performed in one month period. 3. patients who signed study informed consent form. exclusion criteria: 1. coronary and valvular heart disease 2. atrial fibrillation 3. expressed shortness of breath 4. claustrophobia.
cycling deep brain stimulation on parkinson's disease gait

Conditions: Parkinson Disease

Summary: our hypothesis is that cycling dbs stimulation would be superior or non-inferior to regular dbs stimulation in parkinson's disease patients with gait impairment. the objective of this study is compare gait disorders in patients with parkinson's disease and dbs in 4 different scenarios: 1) regular continuous high frequency (\>130hz) stimulation, 2) cycling high frequency (\>130hz) stimulation (40sec on, 2sec off), 3) low-frequency (80hz) continuous stimulation and 4) cycling low frequency (80hz) stimulation (40sec on, 2sec off)

gait disorders such as falls, freezing of gait, reduction of speed, shuffling, and multi-stepped turning are common in patients with moderate and advanced parkinson's disease. compared to appendicular symptoms (bradykinesia, tremor, and rigidity), gait disorders tend to be more resistant to medical and regular deep brain stimulation treatment, and greatly impairs patients' quality of life and daily living activities. some stimulation strategies have been tried to improve gait in parkinson's disease patients, but so far most of them resulted in concomitant worsening of appendicular symptoms. however, new stimulation strategies such as cycling stimulation can potentially improve gait disorders without impairment of appendicular symptoms.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson's disease * currently receiving deep brain stimulation as a parkinson's disease treatment * hoehn \& yahr stage between 2-4 during off-medication * underlying gait disorders despite optimal medical and stimulation treatment: score over or equal to 1 in the subitem 2.12 of the mds-updrs scale * willingness to comply with all study procedures exclusion criteria: * active moderate/severe psychiatric condition * active infection or other uncontrolled moderate/grave comorbidities * treatment with experimental drug * pregnancy or breast-feeding
study of hcv genotype 1 patients in the uk treated with viraferonpeg and rebetol (study p05269)(completed)

Conditions: Hepatitis C, Chronic

Summary: the study is designed as a retrospective data review of medical records from participants selected from specialist secondary and tertiary care centers across the united kingdom (uk), specializing in hepatitis c treatment. the study is non-interventional and is designed to identify subgroups of hepatitis c virus (hcv) genotype 1 participants in the 'real world', including the relation between subgroup characteristics and treatment responsiveness.

physicians will record information (from the time of first exposure to pegylated interferon alfa-2b and ribavirin) from the medical notes of participants who fit the inclusion criteria. to prevent selection bias, data are to be taken from the latest consecutive, unique participants seen by the physician over the previous 48 months. this provides a method of random sampling from a physician practice.

Eligibility criteria:
inclusion criteria: * participants with genotype 1 hcv infection who have been treated with pegylated interferon alfa-2b and ribavirin in the preceding 48 months will be included. they will be divided into: * completer participants: patients with a diagnosis of hcv genotype 1 who have completed a course of interferon alfa-2b and ribavirin, with no prior treatment for hcv (ie, previously treatment naïve). completer participants must have at least 24 weeks of follow up data available post completion of treatment to ensure ability to assess svr rates. * early terminators: participants who have terminated treatment early due to adverse events or other reasons (ie, exposure is incomplete). exclusion criteria: * participants currently undergoing therapy and therefore have not terminated treatment, ie, exposure is still ongoing. * co-infected hcv participants (eg, human immunodeficiency virus \[hiv\] or hepatitis b virus \[hbv\]). * participants who received their first hcv treatment in relation to a clinical trial.
a study of ly2886721 in healthy participants

Conditions: Healthy Volunteers

Summary: the purpose of this phase i study in healthy participants will be to evaluate the safety and tolerability of ly2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the body.


Eligibility criteria:
inclusion criteria: * healthy men and non-childbearing potential women * body mass index (bmi) between 18.0 and 32.0 kilograms per square meter (kg/m\^2) * are reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures and research unit policies exclusion criteria: * taking over-the-counter or prescription medication with the exception of vitamins or minerals * smoke more than 10 cigarettes per day * drink more than 5 cups of caffeine containing beverages (for example, coffee, tea) per day

Keywords: mild cognitive impairment
consensus in surgical community for asymptomatic abdominal wall and incisional hernias

Conditions: Study of Practices of Surgeons on Surgical Management of Asymptomatic Hernias; Comparison With International Recommendations

Summary: hernia pathology is one of the leading causes of surgery worldwide. for asymptomatic patients, surgery remains questionable. although there are new european recommendations, the practice of digestive surgeons regarding the management of asymptomatic hernias is unknown. the objective of this study was to evaluate the practices of a large population of digestive surgeons with asymptomatic hernia.


Eligibility criteria:
inclusion criteria: - exclusion criteria: * no
erythropoietin for the repair of cerebral injury in very preterm infants

Conditions: Intraventricular Hemorrhage of Prematurity

Summary: the purpose of this randomized and placebo-controlled eporepair trial is to evaluate the effect of intravenously administered recombinant human erythropoietin (epo) as compared to placebo in preterm infants with brain damage on neurological development until five years od age.

worldwide, 1% of all infants are born very preterm with less than 32 weeks of gestation, which is more than 2 months before expected date of delivery. if these smallest infants suffer in addition to prematurity a second hit, such as intraventricular hemorrhage or parenchymal infarction, they are at high risk for learning disabilities, mental retardation, and cerebral palsy in later life. intraventricular hemorrhage and parenchymal infarction occur in about 12% of very preterm infants, mostly in the very smallest and within the first few days after birth, and can be recorded by cranial ultrasound. except for shunt insertion to divert cerebrospinal fluid in infants with posthemorrhagic hydrocephalus and possibly the removal of blood clots, there is no treatment for established intracerebral bleeding, and no medical therapies exist to ameliorate the neurodevelopmental sequelae. apart from stimulating production of red blood cells in the bone marrow, recombinant human erythropoietin (epo) has been shown to exert neuroprotective action in a variety of animal models and in clinical studies. epo administration has been found to be beneficial and safe in randomized controlled trials (rct) involving adult and infant patients. observational data suggest that epo administered to very preterm infants in order to prevent from anemia improves long-term cognitive outcomes until school-age especially in those infants who had suffered intracerebral bleeding. these data, however, are observational and therefore do not allow for any firm conclusions or recommendations. the hypothesis generated by these data calls for confirmation or refutation by an rct designed to address this question.

Eligibility criteria:
inclusion criteria: 1. infants with less than 32 weeks of gestation and/or less than 1500 g weight at birth 2. intraventricular hemorrhage and/or hemorrhagic parenchymal infarction 3. less than 8 days of life 4. informed written parental consent exclusion criteria: 1. genetically defined syndrome 2. severe congenital malformation adversely affecting life expectancy and/or neurodevelopment 3. a priory palliative care 4. unlikely to participate at 5-year follow-up examination
the vertos mild™ preliminary patient evaluation study

Conditions: Lumbar Spinal Stenosis

Summary: this is a single-center, open label, prospective clinical study to assess the clinical application and functional outcomes of symptomatic patients undergoing the minimally invasive lumbar decompression (mild™) treatment for lumbar spinal stenosis. in this study, patient-reported outcomes over a 3 month period following treatment will be collected by the investigator. periodic surveys for each study subject's pain, functional status, quality of life and physical examination will track outcomes following mild™ treatment.

the vertos mild™ devices are used for image-guided minimally invasive lumbar decompression, referred to as the mild™ procedure. this percutaneous procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. lumbar decompression is performed through the removal of tissue and bone, where indicated. all procedures are conducted in accordance with the product labeling and indications for use. a minimum of ten up to a maximum of twenty-five adult patients will be enrolled and followed for a period of up to 6 months. patients with symptomatic lumbar spinal stenosis who meet the study enrollment criteria will be offered the mild™ procedure as an alternative to surgery or continued standard non-surgical medical management.

Eligibility criteria:
inclusion criteria: 1. symptomatic lumbar spinal stenosis (lss) primarily caused by dorsal element hypertrophy. 2. prior failure of conservative therapy. 3. radiologic evidence of lss (l3-l5), ligamentum flavum \> 2.5 mm, confirmed by pre op mri and/or ct. 4. central canal cross sectional area \< 100mm2. 5. anterior listhesis \< 2 - 3mm. 6. able to walk at least 10 feet unaided before being limited by pain. 7. available to complete 12 weeks of follow-up. 8. a signed informed consent form is obtained from the patient. 9. adults ≥ 18 years of age. exclusion criteria: 1. prior surgery at intended treatment level. 2. history of recent spinal fractures with concurrent pain symptoms. 3. disabling back or leg pain from causes other than lss (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.). 4. significant disk protrusion or osteophyte formation. 5. excessive facet hypertrophy. 6. bleeding disorders and/or current use of anti coagulants. 7. use of acetylsalicylic acid (asa) and/or non-steroidal anti-inflammatory drug (nsaid) within 5 days of treatment. 8. epidural steroids within prior three weeks. 9. inability of the patient to lie prone for any reason with anesthesia support (e.g. chronic obstructive pulmonary disease (copd), obesity, etc.). 10. any potential wound healing pathologies that may compromise outcomes, including: diabetes, excessive smoking history, cancer, connective tissue diseases, recent spine radiation and severe copd. 11. dementia and/or inability to give informed consent. 12. pregnancy.

Keywords: spinal stenosis lumbar spinal stenosis laminotomy laminectomy spine surgery
im-862 in treating patients with recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: rationale: im-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor. purpose: phase i trial to study the effectiveness of im-862 in treating patients who have recurrent ovarian cancer after treatment with chemotherapy and surgery.

objectives: i. determine the maximum tolerated dose of im-862 administered intranasally in patients with recurrent ovarian cancer. ii. determine the toxicity of this regimen in this patient population. iii. obtain preliminary data regarding the efficacy of this drug in these patients. iv. evaluate the effect of this drug in serum levels of vascular endothelial growth factor and transforming growth factor in this population. outline: this is a dose escalation study. patients receive im-862 intranasally daily. treatment continues for 6 months in the absence of unacceptable toxicity or disease progression. at the physician's discretion, further treatment may be given if the patient is still responding after 6 months of treatment. the dose of im-862 is escalated in cohorts of 10-20 patients until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 3 of 10 or 5 of 20 patients experience dose limiting toxicity. projected accrual: a total of 20-70 evaluable patients will be accrued for this study within 6-9 months.

Eligibility criteria:
disease characteristics: histologically proven recurrent ovarian cancer failed or relapsed after cytoreductive surgery followed by a platinum-based chemotherapy regimen measurable or evaluable disease recurrent disease manifested by isolated increased levels of ca-125 and no other evaluable disease eligible if ca-125 is at least 100 patient characteristics: age: 18 and over performance status: swog 0-2 life expectancy: not specified hematopoietic: absolute granulocyte count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than upper limit of normal (uln) alt and/or ast no greater than 2.5 times uln renal: creatinine no greater than 2 times uln neurological: no evidence of moderate peripheral neuropathy greater than grade 1 other: not pregnant fertile patients must use effective contraception no medical, social, or psychological factors interfering with compliance prior concurrent therapy: biologic therapy: no prior im-862 no concurrent biologic therapy (e.g., interleukin-2 and interferons) chemotherapy: see disease characteristics recovered from prior chemotherapy no concurrent antineoplastic cytotoxic agents endocrine therapy: not specified radiotherapy: recovered from prior radiotherapy surgery: see disease characteristics recovered from prior surgery other: no other concurrent investigational drugs

Keywords: recurrent ovarian epithelial cancer
effect of 120mg somatuline autogel at different dose intervals (28, 42 or 56 days) in patients with acromegaly

Conditions: Acromegaly

Summary: a multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of lanreotide autogel 120mg according to international standards and compared to previous treatment with octreotide lar 10, 20 or 30 mg.

six repeated applications of lanreotide autogel 120mg administered every 28, 42 or 56 days. for the first three injections, the interval depends on the octreotide lar dosage administered previously. the dose interval is titrated after injection 3 depending on the efficacy of the therapy with lanreotide autogel

Eligibility criteria:
inclusion criteria: * the patient must give written (personally signed and dated) informed consent before completing any study-related procedure. * the patient must have a documented diagnosis of active acromegaly and be adequately treated with a stable dose (10, 20 or 30 mg) of octreotide lar for at least 6 months immediately prior to study entry. a documented diagnosis of active acromegaly is defined as igf-1 more than 30% higher than two standard deviations ( +2 sd) above the normal age and sex adjusted value (see appendix 6) or gh level after ogtt (oral glucose tolerance test) \> 2ng/ml while not under drug treatment for acromegaly. for patients having undergone surgery or radiotherapy, this diagnosis must have been performed after the most recent surgical or radiation treatment exclusion criteria: * the patient has had pituitary surgery (adenomectomy) within 6 months prior to study entry * the patient has received stereotactic (linac, gamma knife) radiotherapy for acromegaly within three years or conventional radiotherapy for acromegaly within five years prior to study entry

Keywords: inappropriate growth hormone secretion syndrome (acromegaly)
postprandial fatty acids and fabp2 in type 2 diabetes mellitus (dm)

Conditions: Dyslipidemia; Type 2 Diabetes Mellitus

Summary: this study will be conducted in type 2 diabetic patient's to evaluate the if there is a different response of serum lipids after a standard meal (rich in saturated fatty acids) in patients who have the presence of a genetic alteration. this alteration that will be evaluated is a polymorphism, change of an amino acid in the gene of fabp2. this gene that can influence the absorption of lipids in the intestine and subjects who have the altered genotype (presence of t allele) can have an abnormal lipid profile as compared to subjects without this genotype.

background: the presence of ala54thr polymorphism of intestinal fatty acid-binding protein 2 gene (fabp2) might influence the intestinal absorption of dietary fatty acids (fas) and has been associated with diabetic nephropathy. objective: we studied the postprandial serum fas in type 2 diabetic patients homozygous for thr54 (tt; n = 11) or for ala54 (aa; n = 15) after a standard meal.design: patients received a sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate) in the morning after 12-h fasting and fas in chylomicrons (gas chromatograph), plasma glucose, and serum triacylglycerols were measured at 0, 2, 4, 6 and 8 h. results: tt and aa patients did not differ regarding age (61.6±6.7 vs. 62.0±7.7years), diabetes duration (12.7±6.9 vs. 13.1±5.6years), male proportion (72.7 vs. 86.7%), blood pressure, type of diabetes treatment and previous macronutrients intake as well as serum a1c test (6.5±0.6 vs. 6.7±0.4%), ldl (3.0±1.0 vs. 3.2±0.6mmo/l), hdl (1.3±0.2 vs. 1.3±0.4mmol/l), triacylglycerols \[1.6(1.0-3.4) vs. 1.6(0.6-3.7)mmol/l\], saturated, monounsaturated, and polyunsaturated fas, and trans-unsaturated fas. the increase in serum glucose and triacylglycerols after the meal (anova,p\<0.001) was not different in both groups. the maximum increase of fas occurred at 6-h postprandial, but only in tt patients: saturated fas increased from 464.4(56.9-1602.5) to 1249.5(214.5-7149.8)mg/dl (p=0.041), monounsaturated fas from 387.9(30.2-1523.8) to 925.1(344.6-5554.0)mgd/l (p=0.026), polyunsaturated fas from 258.9(0-1048.5) to 713.1(143.7-7987.6)mg/dl (p=0.021), trans-unsaturated fas from 18.5(1.9-70.6) to 66.5(5.0-451.7)mg/dl (p=0.023). conclusion: the presence of the t allele of ala54thr polymorphism of fabp2 gene in type 2 diabetic patients increases absorption of dietary fas, including the trans-unsaturated fas, and this might turns these patients more susceptible to the effect of diet composition.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * homozygote to fabp2 polymorphism:tt or aa exclusion criteria: * age \>75 years * glomerular filtration rate \<30ml min-1 * with unstable angina or possible infarct or stroke in the last year

Keywords: serum fatty acids fabp2 gene polymorphism ala54thr